Pre-made Belimumab benchmark antibody ( Whole mAb, anti-TNFSF13B therapeutic antibody, Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Belimumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States, Canada, and the European Union to treat systemic lupus erythematosus (SLE).
| Products Name (INN Index) | Pre-Made Belimumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody |
|---|---|
| INN Name | Belimumab |
| Target | TNFSF13B |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE |
| 99% SI Structure | None |
| 95-98% SI Structure | 6erx:HI:DE:QR:MN:FG:OP |
| Year Proposed | 2003 |
| Year Recommended | 2004 |
| Companies | Assistance Publique Hopitaux de Paris,Cancer Trials Australia,GlaxoSmithKline,Hospital for Special Surgery,Human Genome Sciences,North Shore-Long Island Jewish Health System,University of Alabama at |
| Conditions Approved | Systemic lupus erythematosus,Lupus nephritis |
| Conditions Active | Anti-neutrophil cytoplasmic antibody-associated vasculitis,Myositis,Emphysema,Membranous glomerulonephritis,Myasthenia gravis,Renal transplant rejection,Systemic scleroderma,Graft-versus-host disease |
| Conditions Discontinued | Waldenstrom's macroglobulinaemia,Rheumatoid arthritis,Sjogren's syndrome |
| Development Tech | CAT Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | TNFSF13B |
| Package |
